X4 Pharmaceuticals
XFOR
49 hedge funds and large institutions have $15.5M invested in X4 Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 12 closing their positions.
497% more call options, than puts
Call options by funds: $191K | Put options by funds: $32K
9% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 11
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.2% less ownership
Funds ownership: 1.94% → 1.74% (-0.2%)
13% less funds holding
Funds holding: 56 → 49 (-7)
46% less capital invested
Capital invested by funds: $28.7M → $15.5M (-$13.2M)
58% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$390K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$78.6K |
| 3 |
Renaissance Technologies
New York
|
+$54.6K |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$49.5K |
| 5 |
KAS
Kestra Advisory Services
Austin,
Texas
|
+$41.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$414K |
| 2 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$309K |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$199K |
| 4 |
Jane Street
New York
|
-$64K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$62K |
XFOR Hedge Fund Activity: Q2 2022 in Review
49 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q2 2022, worth a combined $15.5M — down 46% from $28.7M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of XFOR and 5 opened new positions — a net loss of 7 holders — while 11 trimmed existing stakes and 12 added.
The largest buyer was Ikarian Capital, adding an estimated $390K. The largest seller was Millennium Management, cutting an estimated $414K.
- 49 institutional investors held X4 Pharmaceuticals (XFOR) as of Q2 2022, down from 56 in Q1 2022.
- Funds reported $15.5M of X4 Pharmaceuticals stock for Q2 2022, down 46% quarter-over-quarter.
- 5 funds opened new X4 Pharmaceuticals positions in Q2 2022 and 12 closed out, a net change of -7 holders.
- The largest X4 Pharmaceuticals buyer in Q2 2022 was Ikarian Capital, an estimated $390K added.
- The largest X4 Pharmaceuticals seller in Q2 2022 was Millennium Management, an estimated $414K sold.
Based on aggregated 13F filings for Q2 2022.